Trophic positions of omnivores are not always flexible: Evidence from four species of freshwater crayfish

Omnivores are generally believed to be flexible in their diet and trophic position: seasonal, ontogenetic and site‐based differences in trophic position have been observed. We compared consumed and assimilated diet among four species within a group of omnivorous freshwater crayfish, to determine whether species that occur together at a site occupy different trophic positions. Diets of Geocharax falcata, Gramastacus insolitus, Cherax destructor and Euastacus bispinosus (Decapoda: Parastacidae) were compared using stable isotopes (δ¹³C and δ¹⁵N) and gut content analysis across nine sites that varied in their species composition. Gramastacus insolitus consumed mainly plant material across all sites. Geocharax falcata consumed either plants or animals or both at different sites. Its trophic level was consistently similar to G. insolitus, despite differences in gut contents and source for dietary carbon. Cherax destructor consumed animals and had a relatively stable trophic position among sites. Relative trophic position of these three species was consistent across sites and regardless of food consumed, they were positioned as omnivores at a lower trophic level than predators but higher than primary producers and herbivores. Euastacus bispinosus occupied a higher trophic level than other invertebrate species but δ¹³C levels did not differ among sites. Cherax destructor and G. falcata may show flexibility in food sources and in the assimilation of food that determines their trophic position relative to other crayfish species. In contrast, G. insolitus and E. bispinosus are likely to show both a more fixed diet and less flexible trophic position. Therefore, not all omnivores show the flexible diet and trophic position generally reported in the literature. Some species of omnivorous crayfish may maintain a relatively constant trophic position across sites, seasons or changes in food availability regardless of whether their consumed diet alters or not.     

Study of response of Swiss Webster mice to light subunit of mushroom tyrosinase

The light subunit of mushroom, Agaricus bisporus, tyrosinase (LSMT), has been identified as an extrinsic component of the enzyme. Its function is unknown, but it can cross an epithelial cell layer, which suggests that it can be absorbed by the intestine. A similar capability has been demonstrated for the HA-33 component of the progenitor toxin from Clostridium botulinum, which is the closest structural homolog of LSMT. Unlike HA-33, LSMT appears to be non-immunogenic as shown by preliminary tests in Swiss Webster mice. We investigated the immunogenicity and histopathology of LSMT in mice to determine its safety in vivo. LSMT did not evoke generation of antibodies after prolonged periods of intraperitoneal administration. Histopathological observations confirmed the absence of responses in organs after twelve weekly administrations of LSMT. We found that LSMT is not toxic and is less immunogenic than the C. botulinum HA-33 protein, which supports further research and development for pharmaceutical application.     

Changes in protein expression during honey bee larval development

Background  

The honey bee (Apis mellifera), besides its role in pollination and honey production, serves as a model for studying the biochemistry of development, metabolism, and immunity in a social organism. Here we use mass spectrometry-based quantitative proteomics to quantify nearly 800 proteins during the 5- to 6-day larval developmental stage, tracking their expression profiles.     

Severe asthma and the omalizumab option

Atopic diseases and asthma are increasing at a remarkable rate on a global scale. It is now well recognized that asthma is a chronic inflammatory disease of the airways. The inflammatory process in many patients is driven by an immunoglobulin E (IgE)-dependent process. Mast cell activation and release of mediators, in response to allergen and IgE, results in a cascade response, culminating in B lymphocyte, T lymphocyte, eosinophil, fibroblast, smooth muscle cell and endothelial activation. This complex cellular interaction, release of cytokines, chemokines and growth factors and inflammatory remodeling of the airways leads to chronic asthma. A subset of patients develops severe airway disease which can be extremely morbid and even fatal. While many treatments are available for asthma, it is still a chronic and incurable disease, characterized by exacerbation, hospitalizations and associated adverse effects of medications. Omalizumab is a new option for chronic asthma that acts by binding to and inhibiting the effects of IgE, thereby interfering with one aspect of the asthma cascade reviewed earlier. This is a humanized monoclonal antibody against IgE that has been shown to have many beneficial effects in asthma. Use of omalizumab may be influenced by the cost of the medication and some reported adverse effects including the rare possibility of anaphylaxis. When used in selected cases and carefully, omalizumab provides a very important tool in disease management. It has been shown to have additional effects in urticaria, angioedema, latex allergy and food allergy, but the data is limited and the indications far from clear. In addition to decreasing exacerbations, it has a steroid sparing role and hence may decrease adverse effects in some patients on high-dose glucocorticoids. Studies have shown improvement in quality of life measures in asthma following the administration of omalizumab, but the effects on pulmonary function are surprisingly small, suggesting a disconnect between pulmonary function, exacerbations and quality of life. Anaphylaxis may occur rarely with this agent and appropriate precautions have been recommended by the Food and Drug Administration (FDA). As currently practiced and as suggested by the new asthma guidelines, this biological agent is indicated in moderate or severe persistent allergic asthma (steps 5 and 6).